skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: 211-astatine containing radiotherapeutics for the treatment of cancer

Abstract

Described herein is an alpha-emitting radionuclide, 211At, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (I), wherein R1-R4, m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a breast cancer model. In one embodiment, the compound is 5-(211At)—N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2,3-dimethoxybenzamide.

Inventors:
; ; ;
Issue Date:
Research Org.:
Univ. of Pennsylvania, Philadelphia, PA (United States)
Sponsoring Org.:
USDOE Office of Science (SC), Biological and Environmental Research (BER)
OSTI Identifier:
1600218
Patent Number(s):
10457642
Application Number:
15/571,055
Assignee:
The Trustees of the University of Pennsylvania (Philadelphia, PA)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
G - PHYSICS G21 - NUCLEAR PHYSICS G21H - OBTAINING ENERGY FROM RADIOACTIVE SOURCES
DOE Contract Number:  
SC0012476
Resource Type:
Patent
Resource Relation:
Patent File Date: 04/26/2016
Country of Publication:
United States
Language:
English

Citation Formats

Pryma, Daniel A., Lieberman, Brian P., Makvandi, Mehran, and Mach, Robert H. 211-astatine containing radiotherapeutics for the treatment of cancer. United States: N. p., 2019. Web.
Pryma, Daniel A., Lieberman, Brian P., Makvandi, Mehran, & Mach, Robert H. 211-astatine containing radiotherapeutics for the treatment of cancer. United States.
Pryma, Daniel A., Lieberman, Brian P., Makvandi, Mehran, and Mach, Robert H. Tue . "211-astatine containing radiotherapeutics for the treatment of cancer". United States. https://www.osti.gov/servlets/purl/1600218.
@article{osti_1600218,
title = {211-astatine containing radiotherapeutics for the treatment of cancer},
author = {Pryma, Daniel A. and Lieberman, Brian P. and Makvandi, Mehran and Mach, Robert H.},
abstractNote = {Described herein is an alpha-emitting radionuclide, 211At, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (I), wherein R1-R4, m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a breast cancer model. In one embodiment, the compound is 5-(211At)—N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2,3-dimethoxybenzamide.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2019},
month = {10}
}

Patent:

Save / Share:

Works referenced in this record:

Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors
patent, June 2008


Phenoxazine derivatives and methods of use thereof
patent, May 2014


Isatin analogues and uses therefor
patent, December 2012


Therapeutic uses of bicyclic ligands of sigma 2 receptor
patent, May 2012


1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
patent, May 2014


Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors
patent, November 2009


Modular platform for targeted therapeutic delivery
patent, March 2012


Compounds, compositions, and methods for cancer imaging and therapy
patent, July 1999


Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand
patent, February 2014


Detection of cancer cells in vitro using sigma-2 receptor ligands as radiotracers
patent, February 2011


Sigma 2 receptor ligands and therapeutic uses therefor
patent, November 2009